yeztugo lenacapavir - Search News

News

HIV, Yeztugo and FDA-approved

FDA Approves Twice-Yearly Yeztugo for Preexposure Prophylaxis to Cut HIV Risk

The U.S. Food and Drug Administration has approved Yeztugo (lenacapavir), an injectable HIV-1 capsid inhibitor, as preexposure prophylaxis (PrEP) to reduce the risk for sexually acquired HIV. The approval is for adults and adolescents weighing at least 35 kg and is the first and only twice-yearly option

MPR · 5h

Twice-Yearly HIV-1 PrEP Yeztugo Gets FDA Approval

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

Greek Reporter · 2h

FDA Approves New HIV Prevention Shot Given Twice a Year

The US Food and Drug Administration (FDA) has approved a new shot to prevent HIV, offering a long-acting alternative to daily pills.

BMO says lenacapavir approval for prevention a ‘major win’ for Gilead

Although largely as expected by investors, BMO Capital says lenacapavir’s approval for prevention, now known as Yeztugo, marks “a major win for Gilead (GILD)” in driving meaningful growth in its ...

Managed Healthcare Executive1d

Lenacapavir HIV PrEP: Not an AIDS Vaccine, but Vaccine Adjacent

Experts and advocates say that twice-a-year HIV PrEP injections have the prevention potential of a vaccine — and that a once-a-year version of lenacapavir would be even better. But will Yeztugo be ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

News

HIV, Yeztugo and FDA-approved

Trending now